Xeris Biopharma Holdings Inc (XERS)
3.31
+0.08
(+2.48%)
USD |
NASDAQ |
Nov 04, 13:14
Xeris Biopharma Holdings Debt to Equity Ratio: -11.95 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | -11.95 |
| March 31, 2024 | -25.02 |
| December 31, 2023 | -28.15 |
| September 30, 2023 | 49.27 |
| June 30, 2023 | 13.80 |
| March 31, 2023 | 6.244 |
| December 31, 2022 | 4.14 |
| September 30, 2022 | 2.516 |
| June 30, 2022 | 1.867 |
| March 31, 2022 | 1.430 |
| December 31, 2021 | 0.9248 |
| September 30, 2021 | -35.64 |
| June 30, 2021 | 4.398 |
| March 31, 2021 | 1.966 |
| Date | Value |
|---|---|
| December 31, 2020 | 2.578 |
| September 30, 2020 | 8.328 |
| June 30, 2020 | 4.490 |
| March 31, 2020 | 2.161 |
| December 31, 2019 | 4.039 |
| September 30, 2019 | 1.331 |
| June 30, 2019 | 0.4332 |
| March 31, 2019 | 0.3001 |
| December 31, 2018 | 0.4229 |
| September 30, 2018 | 0.3327 |
| June 30, 2018 | 0.1662 |
| March 31, 2018 | 0.5495 |
| December 31, 2017 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-35.64
Minimum
Sep 2021
49.27
Maximum
Sep 2023
0.3883
Average
2.516
Median
Sep 2022
Debt to Equity Ratio Benchmarks
| Zoetis Inc | 1.322 |
| Zevra Therapeutics Inc | 1.796 |
| NovaBay Pharmaceuticals Inc | -1.128 |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | 0.0461 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 331.73M |
| Total Liabilities (Quarterly) | 351.02M |
| Shareholders Equity (Quarterly) | -19.29M |
| Current Ratio | 2.256 |
| Net Debt Paydown Yield | -2.56% |